Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis

Health Services Research

Volumn 45, Issue 5 PART 1, 2010, Pages 1227-1250

  Karaca Mandic, Pinar ^a   Joyce, Geoffrey F ^b   Goldman, Dana P ^b   Laouri, Marianne ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Quorum Consulting Inc   (United States)

Author keywords

household burden; pharmacy benefit design; Specialty drugs

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BENEFIT GENEROSITY; BILLING AND CLAIMS; BIOLOGICAL THERAPY; COMORBIDITY; DRUG COST; FAMILY HEALTH; FEMALE; HEALTH CARE UTILIZATION; HOUSEHOLD; HOUSEHOLD FINANCIAL BURDEN; HUMAN; INSURANCE; MALE; REIMBURSEMENT; RHEUMATOID ARTHRITIS;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST SHARING; DRUG COSTS; DRUG UTILIZATION; FEMALE; FINANCING, PERSONAL; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH SERVICES RESEARCH; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INSURANCE CLAIM REPORTING; INSURANCE COVERAGE; MALE; MEDICARE PART D; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTORS, TUMOR NECROSIS FACTOR; UNITED STATES;

EID: 77956604314     PISSN: 00179124     EISSN: 14756773     Source Type: Journal    
DOI: 10.1111/j.1475-6773.2010.01117.x     Document Type: Article

References (35)

1. Allison, P. D. 1982 Discrete-Time Methods for the Analysis of Event Histories In Sociological Methodology, edited by L. Samuel, pp. 61 98. San Francisco : Jossey-Bass.
2. Cunningham, P. J. 2005 Medicaid Cost Containment and Access to Prescription Drugs Health Affairs 24 (3) : 780 789.
3. Furst, D. E., E. C. Keystone, F. C. Breedveld, J. R. Kalden, J. S. Smolden, C. E. Antoni, G. R. Burmeister, L. J. Crofford A. Kavanaugh. 2001 Updated Consensus Statement on Tumor Necrosis Factor Blocking Agents for the Treatment of Rheumatoid Arthritis and Other Rheumatic Diseases Annals of Rheumatic Disease 60 : 2 5.
4. Gaynor, M., J. Li W. B. Vogt. 2007 Substitution, Spending Offsets, and Prescription Drug Benefit Design Forum For Health Economics and Policy 10 : 1 31.
5. Geborek, P., M. Crnkic, I. F. Petersson T. Saxne. 2002 Etanercept, Infliximab, and Leflunomide in Established Rheumatoid Arthritis: Clinical Experience Using a Structured Follow-Up Program in Southern Sweden Annals of Rheumatic Disease 61 : 793 798.
6. Goldman, D., G. Joyce, J. Escarce, J. E. Pace, M. D. Solomon, M. Laouri, P. B. Landsman S. M. Teutsch. 2004 Pharmacy Benefits and the Use of Drugs by the Chronically Ill Journal of American Medical Association 291 (19) : 2344 2350.
7. Goldman, D., G. Joyce, G. Lawless, W. H. Crown V. Willey. 2006a Benefit Design and Specialty Drug Use Health Affairs 25 (5) : 1319 1331.
8. Goldman, D. P., G. F. Joyce P. Karaca-Mandic. 2006b Varying Pharmacy Benefits with Clinical Status: The Case of Cholesterol-Lowering Therapy American Journal of Managed Care 12 (1) : 21 8.
9. Goldman, D. P., G. F. Joyce Y. Zheng. 2007 Prescription Drug Cost Sharing Journal of the American Medical Association 298 (1) : 61 9.
10. Groban, M. D., R. M. Evans, B. Edgren, L. T. Butt, A. D. Stefano, A. De, D. J. Fernandes D. A. Buchner. 1998 Clinical Benefits and Cost Reduction Associated with a Comprehensive Asthma Management Programme at a Managed Care Organization Disease Management and Health Outcomes 4 (2) : 93 100.
11. Hoadley, J., E. Hargrave, J. Cubanski T. Neuman. 2009. Medicare Part D 2009 Data Spotlight, Specialty Tiers. The Henry J. Kaiser Family Foundation, June 2009.
12. Hochberg, M. C., J. K. Tracy, M. Hawkins-Holt R. H. Flores. 2003 Comparison of the Efficacy of the Tumor Necrosis Factor Blocking Agents Adalimumab, Etanercept, and Infliximab When Added to Methotrexate in Patients with Active Rheumatoid Arthritis Annals of Rheumatic Disease 62 (suppl II) : ii13 6.
13. Huskamp, H. A., P. A. Deverka, A. M. Epstein, K. A. McGuigan R. G. Frank. 2003 The Effect of Incentive-Based Formularies on Prescription Drug Utilization and Spending New England Journal of Medicine 349 (23) : 2224 2232.
14. Joyce, G., J. Escarce, M. Solomon D. P. Goldman. 2002 Employer Drug Benefit Plans and Spending on Prescription Drugs Journal of the American Medical Association 288 (14) : 1733 1739.
15. Katz, J. N., J. Barrett, M. H. Liang, A. M. Bacon, H. Kaplan, R. I., Kieval, et al. 1997 Sensitivity and Positive Predictive Value of Medicare Part B Physician Claims for Rheumatologic Diagnoses and Procedures Arthritis and Rheumatism 40 (9) : 1594 1600.
16. Kavanaugh, A., E. W. St. Clair, W. J. McCune, T. Braakman P. Lipsky. 2000 Chimeric Anti-Necrosis Factor-alpha Monoclonal Antibody Treatment of Patients with Rheumatoid Arthritis Receiving Methotrexate Therapy Journal of Rheumatology 27 : 841 850.
17. Lipsky, P. E., D. M. van der Heijde, E. W. St. Clair, D. E. Furst, F. C. Breedveld, J. R. Kalden, J. S. Smolen, N. Weisman, P. Emery, M. Feldmann, G. R. Harriman R. N. Maini. 2000 Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group New England Journal of Medicine 343 : 1594 1602.
18. Losina, E., J. Barrett, J. A. Baron J. N. Katz. 2003 Accuracy of Medicare Claims Data for Rheumatologic Diagnoses in Total Hip Replacement Recipients Journal of Clinical Epidemiology 56 : 515 519.
19. Maini, R., E. W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann P. Lipsky. 1999 Infliximab (Chimeric Anti-Tumor Necrosis Factor Alpha Monoclonal Antibody) versus Placebo in Rheumatoid Arthritis Patients Receiving Concomitant Methotrexate: A Randomized Phase III Trial. ATTRACT Study Group Lancet 354 : 1932 1939.
20. McCulloch, D. 2000 Managing Diabetes for Improved Health and Economic Outcomes The American Journal of Managed Care 6 (21) : S1089 95.
21. Moreland, L. W., M. H. Schiff, S. W. Baumgartner, E. A. Tindall, R. M. Fleischmann, K. J. Bulpitt, A. L. Weaver, E. C. Keystone, D. E. Furst, P. J. Mease, E. M. Ruderman, D. A. Horwitz, D. G. Arkfeld, L. Garrison, D. J. Burge, C. M. Blosch, M. Lange, N. D. McDonnell M. E. Weinblatt. 1999 Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial Annals of Internal Medicine 130 : 478 486.
22. Motheral, B. R. K. A. Fairman. 2001 Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization Medical Care 39 (12) : 1293 1304.
23. Mpofu, S., F. Fatima R. J. Moots. 2005 Review: Anti-TNF-alpha Therapies: They Are All the Same (Aren't They?) Rheumatology 44 : 271 273.
24. Pauly, M. 1968 The Economics of Moral Hazard: Comment American Economic Review 58 : 531 537.
25. Phillips, C. R. L. N. Larson. 1997 Evaluating the Operational Performance and Financial Effects of a Drug Prior Authorization Program Journal of Managed Care Pharmacy 3 (6) : 699 706.
26. Rau, R. 2002 Adalimumab (a Fully Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in the Treatment of Active Rheumatoid Arthritis: The Initial Results of Five Trials Annals of Rheumatic Disease 61 (suppl II) : ii70 3.
27. Rizzo, J. A. W. R. Simons. 1997 Variations in Compliance among Hypertensive Patients by Drug Class: Implications for Health Care Costs Clinical Therapeutics 19 (6) : 1446 1457 discussion 1424-5.
28. Singh, J. A., A. R. Holmgren S. Noorbaloochi. 2004 Accuracy of Veterans Administration Databases for a Diagnosis of Rheumatoid Arthritis Arthritis and Rheumatism 51 (6) : 952 957.
29. Smalley, W. E., M. R. Griffin, R. L. Fought, L. Sullivan W. A. Ray. 1995 Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Anti-Inflammatory Drugs by Medicaid Patients The New England Journal of Medicine 332 (24) : 1612 1617.
30. Sokol, M. C., K. A. McGuigan, R. R. Verbrugge R. S. Epstein. 2005 Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost Medical Care 43 (6) : 521 530.
31. Solomon, M. D., D. P. Goldman, G. F. Joyce J. Escarce. 2009 Cost Sharing and the Initiation of Drug Therapy for the Chronically Ill Archives of Internal Medicine 169 (8) : 74 748.
32. Thompson, D., T. R. Hylan, W. McMullen, M. E. Romeis, D. Bueschline G. Oster. 1998 Predictors of a Medical-Offset Effect among Patients Receiving Antidepressant Therapy The American Journal of Psychiatry 155 (6) : 824 827.
33. Van den Bulte, C. G. Lilien. 2001 Medical Innovation Revisited: Social Contagion versus Marketing Effort American Journal of Sociology 106 (5) : 1409 1435.
34. Wei, L., J. Wang, P. Thompson, S. Wong, A. D. Struthers T. M. MacDonald. 2002 Adherence to Statin Treatment and Readmission of Patients after Myocardial Infarction: A Six-Year Follow-Up Study Heart 88 (3) : 229 233.
35. Weinblatt, M. E., J. M. Kremer, A. D. Bankhurst, K. J. Bulpitt, R. M. Fleischmann, R. I. Fox, C. O. Jackson, M. Lange D. J. Burge. 1999 A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate The New England Journal of Medicine 340 : 253 259.